Gilead Sciences announced data from its Phase 3 (Study 145) trial of elvitegravir for the treatment of HIV-1 infection. Study 145 was a double-blind, multicenter, randomized, active-controlled, 96-week trial evaluating the non-inferiority of elvitegravir (n=351) vs. raltegravir (n=351), administered with a ritonavir-boosted protease inhibitor.
After 96 weeks of treatment, 48% of patients receiving ritonavir-boosted elvitegravir achieved and maintained HIV RNA levels (viral load) <50 copies/mL, compared to 45% of patients receiving raltegravir, based on the Time to Loss of Virologic Response algorithm (TLOVR) (95% CI: -4.6% – 9.9%).
Elvitegravir is an integrase inhibitor that interferes with HIV replication by blocking the ability of the virus to integrate into the genetic material of human cells.
For more information call (800) GILEAD-5 or visit www.gilead.com.